Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Bnai Zion Medical Center.
Recruitment status was  Recruiting
Information provided by:
Bnai Zion Medical Center Identifier:
First received: September 22, 2009
Last updated: July 18, 2010
Last verified: July 2010
Chronic pain due to calcific tendonitis of shoulder is a prevalent condition usually treated with recurrent courses of NSAIDs, physical therapy or surgical interventions. Colchicine has been reported to be effective in the acute attack of shoulder tendonitis, however, has never been examined in controlled study in patients with chronic shoulder pain secondary to calcific tendonitis. Eighty patients with chronic shoulder pain (at least 3 months duration) due to calcific tendonitis will be randomized to receive colchicine 0.5 mg twice daily or placebo (lactose capsules) for 4 months. At the end of this blinded part of the study, patients who received placebo and did not improve, will be eligible to continue study in the open mode for additional 4 months with study drug. Efficacy (VAS for shoulder pain, shoulder range of motion and shoulder pain and disability index) and safety (blood tests) follow-ups will be scheduled bi-monthly for all patients.

Condition Intervention
Calcific Tendonitis
Drug: Colchicine
Drug: lactose

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Colchicine Treatment for Chronic Shoulder Pain Related to Calcific Tendonitis: Double Blind Placebo-controlled Study

Resource links provided by NLM:

Further study details as provided by Bnai Zion Medical Center:

Primary Outcome Measures:
  • VAS for shoulder pain [ Time Frame: 4-8 months ] [ Designated as safety issue: No ]
  • shoulder range of motion [ Time Frame: 4-8 months ] [ Designated as safety issue: No ]
  • shoulder pain and disability index [ Time Frame: 4-8 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 80
Study Start Date: March 2010
Estimated Study Completion Date: October 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: colchicine Drug: Colchicine
0.5 mg twice daily for 4 months
Placebo Comparator: Lactose capsule Drug: lactose
lactose capsules twice daily


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • chronic, more than 3 months duration, shoulder pain
  • tendinous calcifications on shoulder X-rays

Exclusion Criteria:

  • renal insufficiency
  • liver insufficiency
  • lactose intolerance
  • hypersensitivity to colchicine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00983177

Contact: Gleb Slobodin, MD 972-506267284

Bnai Zion Medical Center Recruiting
Haifa, Israel
Contact: Gleb Slobodin, MD   
Principal Investigator: Gleb Slobodin, MD         
Sponsors and Collaborators
Bnai Zion Medical Center
Study Director: Itzhak Rosner, MD Bnai Zion Medical Center
  More Information

Responsible Party: Gleb Slobodin, Bnai Zion Medical Center Identifier: NCT00983177     History of Changes
Other Study ID Numbers: colchicine1 
Study First Received: September 22, 2009
Last Updated: July 18, 2010
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Shoulder Pain
Joint Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Antimitotic Agents
Antineoplastic Agents
Antirheumatic Agents
Gout Suppressants
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Tubulin Modulators processed this record on May 25, 2016